NURIX
Live / Allowed — Second extension granted (statement of use) (as of 07 Jul 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 06 Sept 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98978249
- Mark type
- Design + words
- Filed
- 06 Sept 2024
- Published for opposition
- 15 Apr 2025
- Attorney of record
- Gazal Pour-Moezzi
Goods and services
- Class 005 — Pharmaceuticals: Biological and pharmaceutical preparations for the treatment of cancer and immune-related disorders
- Class 042 — Scientific and technological services: Research and development in the pharmaceutical and biotechnology fields
Owner
- Nurix Therapeutics, Inc., Brisbane, CA, US
- Nurix Therapeutics, Inc., San Francisco, CA, US
Prior registrations
Prosecution history
- 07 Jul 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 07 Jul 2026 — SOU EXTENSION 2 GRANTED
- 09 Jun 2026 — SOU EXTENSION 2 FILED
- 09 Jun 2026 — SOU TEAS EXTENSION RECEIVED
- 05 Jun 2026 — DIVISIONAL PROCESSING COMPLETE
- 25 Nov 2025 — DIVISIONAL REQUEST RECEIVED
- 27 May 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 22 Apr 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 25 Nov 2025 — TEAS STATEMENT OF USE RECEIVED
- 25 Nov 2025 — TEAS REQUEST TO DIVIDE RECEIVED
- 21 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 21 Nov 2025 — SOU EXTENSION 1 GRANTED
- 20 Nov 2025 — SOU EXTENSION 1 FILED
- 20 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 10 Jun 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT